Carigent

Founded and launched by a group of scientists at the Yale Science Park, Carigent focuses on the development of next-generation therapeutic agents using a propriety platform that is versatile and robust. The platform allows for controlled release of therapeutic agents, tethering of surface ligands, targeting of therapy to a particular physiological site, and the ability to combine multiple agents into one vehicle made primarily from FDA-approved materials.
Next generation therapeutics agents - Carigent Logo

Details:

  • Website: www.carigent.com
  • Investment Type: Seed Investor
  • Status: Current
  • Sector: Biotech
  • Location: Yale Science Park - New Haven, Connecticut

News:

  • www.carigent.com
  • 1/22/08 - Carigent Therapeutics Awarded NSF Phase I SBIR Grant to Advance Development of Paclitaxel-Loaded Targeted Nanoparticles to Treat Ovarian Cancer.
  • 1/16/08 - Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-Hodgkin's Lymphoma.
  • 12/11/07 - Carigent Therapeutics Completes Series A Financing; Advancing Nanotechnology for Controlled Delivery of Targeted Drugs and Diagnostics.